Sickle Cell Disease Clinical Trial Landscape

Why SCD trial monitoring matters in 2026

Sickle cell disease (SCD) is one of the most common severe monogenic disorders worldwide, affecting approximately 300,000 newborns annually and an estimated 100,000 Americans. After decades of limited therapeutic options beyond hydroxyurea and transfusion, the field underwent a historic transformation with gene therapy approvals in late 2023, only to be reshaped again by voxelotor's market withdrawal in 2024.

The SCD competitive landscape entering 2026 is unusually fluid:

• Gene therapy access bottleneck: Casgevy (exa-cel, CRISPR-based, ~$2.2M) and Lyfgenia (betibeglogene, lentiviral, ~$3.1M) approved but real-world uptake is limited by cost, manufacturing capacity, and treatment center availability
• Voxelotor's withdrawal (Sept 2024): Pfizer voluntarily pulled voxelotor globally after a confirmatory trial showed no VOC reduction; this has sharply elevated the competitive stakes for pyruvate kinase activators
• PK activator race: Agios's mitapivat (RISE UP, Phase 2/3) and Novo Nordisk's etavopivat (two Phase 3 trials) are now the leading small-molecule SCD programs for non-gene-therapy patients
• Crizanlizumab reinvestment: Novartis withdrew crizanlizumab from EU (2023, CASTLE trial failure) but is now running SPARKLE with a 2× higher dose in VOC-frequent patients
• New mechanisms entering: Sanofi's rilzabrutinib (BTK inhibitor) brings an anti-inflammatory angle to SCD Phase 3; Pfizer has an undisclosed Phase 2/3 agent (NCT05431088)

Active Phase 3 Landscape: Sickle Cell Disease (2026)

Phase 3 studies are active across gene therapy, PK activators, anti-adhesion, and anti-inflammatory approaches. Key programs:

The Pyruvate Kinase Activator Race Post-Voxelotor

Mitapivat (Agios): RISE UP (NCT05031780)

Mitapivat (brand name Pyrukynd) was already FDA-approved for pyruvate kinase deficiency. The Phase 2/3 RISE UP study enrolled adult SCD patients to evaluate whether PK activation, already proven feasible in a related RBC disorder, translates to SCD. The trial is now active-not-recruiting as data analysis proceeds. Agios has deep experience with mitapivat safety data from PKD and alpha- and beta-thalassemia trials, giving them a safety profile advantage entering SCD data readouts.

Etavopivat (Novo Nordisk): Two Phase 3 Trials

Novo Nordisk has launched two Phase 3 trials for etavopivat in SCD simultaneously:

• NCT06612268: Primary efficacy study in SCD patients, evaluating VOC reduction and hemoglobin response
• NCT06609226: Long-term safety study in both SCD and β-thalassemia patients

Novo Nordisk's entry is significant: it brings substantial commercial infrastructure to the PK activator class at a time when voxelotor's withdrawal has created unmet demand among the SCD patient population not eligible or unable to access gene therapy. The parallel SCD/thalassemia design of the long-term study suggests a cross-indication strategy similar to mitapivat.

The PK activator race will generate a critical competitive data read in 2026: whichever agent demonstrates more robust VOC reduction will likely capture the available small-molecule SCD market.

SPARKLE: Novartis's Renewed Bet on Crizanlizumab

Crizanlizumab's history in SCD is one of the more complex regulatory stories in hematology:

• SUSTAIN (2019): Phase 2b trial at 2.5 mg/kg showed 45% reduction in VOC rate vs. placebo → FDA accelerated approval (2019)
• CASTLE (2023): Phase 3 confirmatory trial at 5 mg/kg and 7.5 mg/kg failed to show VOC reduction vs. placebo → Novartis withdrew from EU market
• SPARKLE (2024–present, NCT06439082): New Phase 3 with a focused design, 5 mg/kg dosing in patients with frequent VOCs (≥2 in the prior 12 months). Hypothesis: endpoint failure in CASTLE may have been driven by patient heterogeneity; a VOC-frequent population may show a clearer effect

SPARKLE is now actively recruiting. For BD teams, the SPARKLE readout will either rehabilitate P-selectin blockade as a validated SCD mechanism or definitively close the crizanlizumab chapter.

Rilzabrutinib: BTK Inhibition Enters SCD Phase 3

Sanofi's rilzabrutinib (NCT06975865) is a Phase 3 SCD trial for patients aged 10–65. This is the same molecule Sanofi is developing across ITP, IgG4-related disease, warm autoimmune hemolytic anemia, and focal segmental glomerulosclerosis, a broad inflammatory/autoimmune portfolio strategy.

The BTK mechanism is orthogonal to P-selectin blockade (crizanlizumab) and to metabolic approaches (PK activators). If rilzabrutinib works in SCD, it would validate a new mechanistic axis and potentially enable combination strategies with anti-sickling agents. For competitive intelligence teams, Sanofi's SCD entry is notable given the company's large hematology/rare disease footprint.

Post-Approval Gene Therapy: The Access Problem

The 2023 approval of Casgevy (Vertex/CRISPR Therapeutics) and Lyfgenia (bluebird bio) was a landmark moment, the first CRISPR therapies and the first gene therapies approved for SCD. But real-world uptake has been limited:

• Cost: Casgevy at ~$2.2M and Lyfgenia at ~$3.1M per patient, among the most expensive therapies ever approved
• Manufacturing complexity: Ex vivo cell engineering creates a long treatment timeline (12–18+ months from cell collection to reinfusion) and requires specialized treatment centers
• Myeloablative conditioning: Full busulfan conditioning is required, carrying risk of infertility, secondary malignancy, and transplant-related mortality
• Authorized Treatment Centers (ATCs): Limited number of qualified centers globally creates geographic access barriers

Active gene therapy programs are addressing these barriers:

• CTX001 pediatric (NCT05329649, Vertex): extending the approved indication to pediatric SCD patients
• CTX001 SCD + thal (NCT05477563, Vertex): broadening the gene therapy population across hemoglobinopathies
• BCL11A enhancer editing (NCT06647979, Bauer/BCH): academic next-gen editing approach
• HBB direct correction (NCT04819841, Kamau Therapeutics): correcting HbS to HbA at the mutation level

The next frontier, in vivo delivery of gene editing machinery to hematopoietic stem cells, remains preclinical/early Phase 1, but would eliminate the ex vivo manufacturing barrier entirely.

What we monitor for sickle cell disease

Our system pulls from the ClinicalTrials.gov API every day. For an SCD watch profile, you can configure a saved search for:

• Condition keywords: "sickle cell disease", "sickle cell anemia", "HbSS", "hemoglobin sickle", "vaso-occlusive crisis", "SCD"
• Drug/target keywords: "etavopivat", "mitapivat", "crizanlizumab", "rilzabrutinib", "CTX001", "BCL11A", "PKR", "P-selectin", "BTK sickle", any target or mechanism you're following
• Phase filter: Phase 1 for early gene therapy programs, Phase 2/3 for near-term competitive data
• Sponsor type: Industry (Novartis, Novo Nordisk, Sanofi, Vertex, Agios, Pfizer), academic (St. Jude, NHLBI, Vanderbilt), or all
• Status changes: New registrations, enrollment opens, status updates, and results postings

Who uses SCD clinical trial monitoring

• Rare disease BD teams: tracking gene therapy, PK activators, anti-adhesion, and anti-inflammatory competitors in SCD
• Hematology investors: monitoring Phase 3 data timelines for Novo Nordisk's etavopivat, Agios's RISE UP readout, SPARKLE, and rilzabrutinib
• Gene therapy commercial teams: tracking next-gen competitors and access programs threatening approved gene therapies
• Patient advocacy organizations: tracking available trial options for SCD patients and families, particularly emerging access programs
• Academic hematologists: staying current on trial availability for patients not eligible for approved gene therapies
• NIH and government researchers: monitoring the commercial landscape alongside the NHLBI and NCI-funded academic programs

Related pages: Multiple Myeloma · AML · CAR-T Therapy · Pharma Pipeline Tracker